Phase 1B study of enzalutamide (ENZA) with or without sorafenib (SORA) in patients (pts) with advanced hepatocellular carcinoma (HCC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.4083
Abstract: 4083Background: Preclinical models indicate that androgen receptor (AR) interference with ENZA is deleterious to HCC; however, ENZA also activates feedback circuitry that may be overcome with the a... read more here.
Keywords: hcc; study enzalutamide; without sorafenib; enza without ... See more keywords